Short answer
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an 8-K current report with the SEC on September 24, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Senator Torricelli and Dr. Miller appointed as directors, expanding board oversight.
CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Senator Torricelli and Dr. Miller appointed as directors, expanding board oversight
- Dr. Miller adds clinical, Medicare policy, regulatory and health-plan governance expertise
- Each receives pro rata board and committee retainers plus prorated RSUs valued at $200,000 annually
- Director indemnification agreements require liability protection and advancement of defense expenses
- No disclosed selection arrangements, family relationships or related-party transaction conflicts
Item EX-99.1 · Exhibit EX-99.1
- Former Senator Robert Torricelli and Dr. Brian J. Miller appointed directors, filling two vacancies
- Board expanded to nine directors, strengthening governance capacity
- Torricelli joins Audit Committee with federal healthcare policy and Clover subsidiary experience
- Miller joins Clinical Committee, adding Medicare payment, regulatory, and practicing physician expertise
- Appointments support Clover’s Medicare Advantage strategy but create no disclosed immediate financial impact
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K filings
Get the next CLOV 8-K as it lands
Follow CLOV for push alerts, or ask the research agent what this filing means.